(Q38732403)

English

A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, an

scientific article published on 02 September 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 September 2017

A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, an (English)

1 reference

Europe PubMed Central

5 September 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

neoadjuvant chemotherapy

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

0 references

author name string

David J McConkey

1

1 reference

Europe PubMed Central

5 September 2017

Woonyoung Choi

2

1 reference

Europe PubMed Central

5 September 2017

Yu Shen

3

1 reference

Europe PubMed Central

5 September 2017

I-Ling Lee

4

1 reference

Europe PubMed Central

5 September 2017

Sima Porten

5

1 reference

Europe PubMed Central

5 September 2017

Surena F Matin

6

1 reference

Europe PubMed Central

5 September 2017

Ashish M Kamat

7

1 reference

Europe PubMed Central

5 September 2017

Paul Corn

8

1 reference

Europe PubMed Central

5 September 2017

Randall E Millikan

9

1 reference

Europe PubMed Central

5 September 2017

Colin Dinney

10

1 reference

Europe PubMed Central

5 September 2017

Bogdan Czerniak

11

1 reference

Europe PubMed Central

5 September 2017

Arlene O Siefker-Radtke

12

1 reference

Europe PubMed Central

5 September 2017

language of work or name

0 references

publication date

2 September 2015

1 reference

Europe PubMed Central

5 September 2017

European Urology

1 reference

Europe PubMed Central

5 September 2017

69

1 reference

Europe PubMed Central

5 September 2017

855-862

1 reference

Europe PubMed Central

5 September 2017

5

1 reference

Europe PubMed Central

5 September 2017

describes a project that uses

1 reference

Europe PubMed Central

22 June 2022

https://europepmc.org/article/PMC/4775435

based on heuristic

inferred from PubMed Central ID database lookup

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4775435

6 September 2017

Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4775435

6 September 2017

Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4775435

6 September 2017

Comprehensive molecular characterization of urothelial bladder carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4775435

6 September 2017

Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4775435

6 September 2017

ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4775435

6 September 2017

A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4775435

6 September 2017

Normal and neoplastic urothelial stem cells: getting to the root of the problem

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4775435

6 September 2017

p63 expression defines a lethal subset of muscle-invasive bladder cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4775435

6 September 2017

Practical implications of gene-expression-based assays for breast oncologists.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4775435

6 September 2017

International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4775435

6 September 2017

Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4775435

6 September 2017

Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4775435

6 September 2017

Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4775435

6 September 2017

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4775435

6 September 2017

Molecular portraits of human breast tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4775435

6 September 2017

EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4775435

6 September 2017

A molecular taxonomy for urothelial carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4775435

14 September 2017

ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4775435

31 August 2018

Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC

1 reference

https://pubmed.ncbi.nlm.nih.gov/26343003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy

1 reference

https://pubmed.ncbi.nlm.nih.gov/26343003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort

1 reference

https://pubmed.ncbi.nlm.nih.gov/26343003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates

1 reference

https://pubmed.ncbi.nlm.nih.gov/26343003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European

1 reference

https://pubmed.ncbi.nlm.nih.gov/26343003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of clinical staging before cystectomy in transitional cell bladder carcinoma: a long-term follow-up of 276 consecutive patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/26343003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.EURURO.2015.08.034

1 reference

Europe PubMed Central

5 September 2017

1 reference

Europe PubMed Central

5 September 2017

1 reference

Europe PubMed Central

5 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38732403&oldid=1665393266"